PINK SHEET
CITELINE REGULATORY

20 Aug 2018 | **Opinion**

QUOTED. Aug. 20, 2018. Bradley Thompson.

by

Attorney and industry advocate Bradley Merrill Thompson argues in a recent *Medtech Insight* article that US FDA is pursuing expanded authorities for collecting and acting on post-market device data without congressional authorization. Read one of Thompson's recommendations here.

"We need Congress to lay out a system that specifies both the process through which CDRH decides to make use of adverse publicity, and standards that define the circumstances in which the center can use that tactic." – Bradley Thompson, attorney, Epstein, Becker & Green

- Find out more: *CDRH's New Post-Market Paradigm: Why The Public Should Be Worried*

Click here for a free trial of *Medtech Insight*